

Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032

Market Report | 2024-12-19 | 263 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global cancer vaccines market is projected to surpass USD 20.47 billion in 2032 from USD 10.61 billion in 2024, with a significant CAGR of 8.6%. The market is witnessing robust growth, fueled by rising cancer prevalence and advancements in immunotherapy technologies like mRNA platforms. Preventive vaccines such as Gardasil (HPV) and therapeutic candidates like neoantigen vaccines are driving innovation in the market. Strong R&D investments, especially in North America and Europe, combined with increasing demand for personalized therapies, are further accelerating adoption.

"The preventive cancer vaccines segment accounted for the highest share in 2023."

On the basis of type, the cancer vaccines market is further segmented into preventive and therapeutic vaccines (Neoantigen cancer vaccines and other cancer vaccines). The preventive cancer vaccines segment is anticipated to lead the cancer vaccines market, driven by increasing awareness of disease prevention, government immunization programs, and technological advancements in vaccine development. Emerging technologies, such as mRNA platforms, are further likely to enhance vaccine efficacy and accessibility is likely to boost the segmental growth.

"By route of administration, intramuscular segment accounted for the largest share in the cancer vaccines market."

The route of administration segment of the cancer vaccines market is segmented into intravenous, intramuscular, and other route of administration. Intramuscular (IM) route of administration is expected to lead the cancer vaccines market owing to the established practice, high efficacy of the administration of the vaccine, and creation of an effective immune response. IM administration guarantees a high efficiency of vaccine absorption and compatibility with any kind of formulation, therefore it is the most appropriate for preventive and treatment cancer vaccines. Its ease of use in clinical and outpatient settings, along with

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

minimal training requirements for healthcare providers, enhances accessibility and scalability for mass immunization programs. All of these parameters therefore position the IM route as the dominant and feasible option in the cancer vaccine field.

"North America: the largest share of the cancer vaccines market"

By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the cancer vaccines market in 2023 and is estimated to continue dominance during the forecast period. Advanced healthcare infrastructure, high levels of investment in biotechnology, and strong presence of leading pharmaceutical companies driving innovation in the field. are some of the prominent factors accelerating market growth.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the cancer vaccines market.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 65% and Demand Side 35%

-□By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

-□By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others are some of the major players operating in the cancer vaccines market.

Research Coverage:

This research report categorizes the cancer vaccines market type (preventive and therapeutic [neoantigen cancer vaccines & other cancer vaccines]), technology (cell-based vaccines, recombinant, others), route of administration (intramuscular, intravenous, other routes of administration), indication (cervical cancer, prostate cancer, other indications), end user (hospitals, others) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cancer vaccines market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the cancer vaccines market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the cancer vaccines and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

-□Analysis of key drivers (Increasing Awareness and Preventive Healthcare Measures, Rising Cancer Incidence Globally, Increased investments into R&D of Neoantigen cancer vaccines and Technological Advancements in Immunotherapy), restraints (Lengthy Clinical Trial Processes and Vaccine Hesitancy & Limited Adoption and High Development and Manufacturing Costs), opportunities (Collaborations & Strategic Partnerships and Incorporation of Artificial Intelligence (AI) & Big Data) and Challenges (Personalized Medicine & Heterogeneity of Cancer Types and Competition from Alternative Therapies) influencing the growth of the market.

-□Product Development/Innovation: Detailed insights on upcoming technologies in cancer vaccines manufacturing, research and development activities, and new product launches in the cancer vaccines market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer vaccines market

-□Competitive Assessment: Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others in the market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

1	INTRODUCTION	26
1.1	STUDY OBJECTIVES	26
1.2	MARKET DEFINITION	26
1.3	MARKET SCOPE	27
1.3.1	MARKETS COVERED & REGIONAL SEGMENTATION	27
1.3.2	INCLUSIONS & EXCLUSIONS	28
1.3.3	YEARS CONSIDERED	28
1.3.4	CURRENCY CONSIDERED	28
1.4	STAKEHOLDERS	29
2	RESEARCH METHODOLOGY	30
2.1	RESEARCH DATA	30
2.1.1	SECONDARY DATA	31
2.1.2	PRIMARY DATA	32
2.2	MARKET ESTIMATION METHODOLOGY	33
2.2.1	MARKET ESTIMATION	33
2.2.2	INSIGHTS FROM PRIMARY EXPERTS	35
2.2.3	TOP-DOWN APPROACH	36
2.3	MARKET GROWTH RATE PROJECTION	37
2.4	DATA TRIANGULATION	39
2.5	RESEARCH ASSUMPTIONS	39
2.6	RESEARCH LIMITATIONS	40
2.7	RISK ANALYSIS	41
3	EXECUTIVE SUMMARY	42
4	PREMIUM INSIGHTS	47
4.1	CANCER VACCINES MARKET OVERVIEW	47
4.2	NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023)	48
4.3	CANCER VACCINES MARKET SHARE, BY TYPE, 2024 VS. 2032	48
4.4	CANCER VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	49
?		
5	MARKET OVERVIEW	50
5.1	INTRODUCTION	50
5.2	MARKET DYNAMICS	50
5.2.1	DRIVERS	51
5.2.1.1	Increased investments in neoantigen cancer vaccine R&D	51
5.2.1.2	Technological advancements in immunotherapy	51
5.2.1.3	Increasing awareness and preventive healthcare measures	52
5.2.1.4	Rising cancer incidence globally	53
5.2.2	RESTRAINTS	53
5.2.2.1	High development and manufacturing costs	53
5.2.2.2	Lengthy clinical trial processes & vaccine hesitancy and limited adoption	54
5.2.3	OPPORTUNITIES	55
5.2.3.1	Collaborations and strategic partnerships	55
5.2.3.2	Incorporation of AI and big data	56
5.2.4	CHALLENGES	57
5.2.4.1	Personalized medicine and heterogeneity of cancer types	57
5.2.4.2	Competition from alternative therapies	57

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS	58
5.4	VALUE CHAIN ANALYSIS	59
5.5	ECOSYSTEM ANALYSIS	60
5.5.1	RAW MATERIAL PROVIDERS	61
5.5.2	PRODUCT PROVIDERS	62
5.5.3	END USERS	63
5.5.4	REGULATORY LANDSCAPE	63
5.6	TECHNOLOGY ANALYSIS	64
5.6.1	KEY TECHNOLOGIES	65
5.6.1.1	mRNA-based vaccines	65
5.6.1.2	Dendritic cell vaccines	65
5.6.1.3	Recombinant vector-based vaccines	66
5.6.2	COMPLEMENTARY TECHNOLOGIES	66
5.6.2.1	Artificial Intelligence (AI) and Machine Learning (ML)	66
5.6.2.2	Adjuvants for immuno-stimulation	66
5.6.3	ADJACENT TECHNOLOGIES	67
5.6.3.1	CAR T-cell therapy	67
5.6.3.2	CRISPR-based gene editing	67
5.7	PATENT ANALYSIS	68
5.7.1	METHODOLOGY	68
5.7.2	NUMBER OF PATENTS FILED	68
5.7.3	INNOVATIONS AND PATENT APPLICATIONS	68
?		
5.8	PRICING ANALYSIS	71
5.8.1	AVERAGE SELLING PRICE TREND OF KEY PLAYERS, 2021-2023	71
5.8.2	AVERAGE SELLING PRICE, BY REGION, 2023	72
5.9	KEY CONFERENCES & EVENTS, 2024-2025	73
5.10	REGULATORY LANDSCAPE	74
5.10.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	74
5.10.2	REGULATORY FRAMEWORK	77
5.10.2.1	North America	77
5.10.2.2	Europe	77
5.10.2.3	Asia Pacific	77
5.11	INVESTMENT & FUNDING SCENARIO	78
5.12	PORTER'S FIVE FORCES ANALYSIS	80
5.12.1	INTENSITY OF COMPETITIVE RIVALRY	81
5.12.2	BARGAINING POWER OF SUPPLIERS	81
5.12.3	BARGAINING POWER OF BUYERS	81
5.12.4	THREAT OF SUBSTITUTES	81
5.12.5	THREAT OF NEW ENTRANTS	81
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	82
5.13.1	KEY STAKEHOLDERS	82
5.13.2	KEY BUYING CRITERIA	83
5.14	TRADE ANALYSIS	85
5.14.1	IMPORT DATA FOR HS CODE 300241	85
5.14.2	EXPORT DATA FOR HS CODE 300241	86
5.15	IMPACT OF AI/GEN AI ON CANCER VACCINES MARKET	88

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.16 PIPELINE ANALYSIS 90
- 6 CANCER VACCINES MARKET, BY TYPE 91
 - 6.1 INTRODUCTION 92
 - 6.2 PREVENTIVE VACCINES 92
 - 6.2.1 NATIONAL IMMUNIZATION PROGRAMS & BIOTECHNOLOGY INNOVATIONS TO DRIVE MARKET GROWTH 92
 - 6.3 THERAPEUTIC VACCINES 95
 - 6.3.1 NEOANTIGEN CANCER VACCINES 99
 - 6.3.1.1 Personalized nature of neoantigen cancer vaccines to propel market growth 99
 - 6.3.2 OTHER THERAPEUTIC VACCINES 102
- 7 CANCER VACCINES MARKET, BY TECHNOLOGY 106
 - 7.1 INTRODUCTION 107
 - 7.2 CELL-BASED VACCINES 107
 - 7.2.1 ADVANCEMENTS IN MANUFACTURING PROCESSES TO DRIVE MARKET GROWTH 107
 - 7.3 RECOMBINANT VACCINES 110
 - 7.3.1 GLOBAL VACCINATION INITIATIVES TO PROPEL MARKET 110
 - 7.4 OTHER VACCINE TECHNOLOGIES 113
- 8 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION 117
 - 8.1 INTRODUCTION 118
 - 8.2 INTRAMUSCULAR ROUTE 118
 - 8.2.1 TECHNOLOGICAL ADVANCEMENTS IN VACCINE DELIVERY TO SUPPORT MARKET GROWTH 118
 - 8.3 OTHER ROUTES OF ADMINISTRATION 121
- 9 CANCER VACCINES MARKET, BY INDICATION 125
 - 9.1 INTRODUCTION 126
 - 9.2 CERVICAL & RELATED CANCERS 126
 - 9.2.1 RISING CERVICAL CANCER PREVALENCE TO SUPPORT MARKET GROWTH 126
 - 9.3 OTHER INDICATIONS 129
- 10 CANCER VACCINES MARKET, BY END USER 133
 - 10.1 INTRODUCTION 134
 - 10.2 HOSPITALS 134
 - 10.2.1 RISING CANCER PREVALENCE TO SUPPORT MARKET GROWTH 134
 - 10.3 SPECIALTY CLINICS & CENTERS 137
 - 10.3.1 INCREASING AWARENESS AND ACCESS TO PROPEL MARKET 137
- 11 CANCER VACCINES MARKET, BY REGION 141
 - 11.1 INTRODUCTION 142
 - 11.2 ASIA PACIFIC 142
 - 11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 143
 - 11.2.2 CHINA 147
 - 11.2.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China 147
 - 11.2.3 JAPAN 150
 - 11.2.3.1 Government initiatives for vaccines to boost market 150
 - 11.2.4 INDIA 152
 - 11.2.4.1 Growth of biotechnology sector and development of new vaccines to drive market 152
 - 11.2.5 SOUTH KOREA 155
 - 11.2.5.1 Commitment to cancer immunotherapy to expand cancer vaccine sector 155
 - 11.2.6 REST OF ASIA PACIFIC 157

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.3	NORTH AMERICA	160
11.3.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	160
11.3.2	US	164
11.3.2.1	US to dominate North American market during forecast period	164
11.3.3	CANADA	167
11.3.3.1	Increasing government funding for vaccine research to drive market growth in Canada	167
11.4	EUROPE	169
11.4.1	MACROECONOMIC OUTLOOK FOR EUROPE	169
11.4.2	GERMANY	173
11.4.2.1	Increasing investments by key players and growing funding from government organizations to drive market	173
11.4.3	UK	175
11.4.3.1	Rising investments in vaccine development to boost market growth	175
11.4.4	FRANCE	178
11.4.4.1	Support for biotechnology and research to drive market growth	178
11.4.5	ITALY	181
11.4.5.1	Government initiatives for vaccine development to boost market growth	181
11.4.6	SPAIN	183
11.4.6.1	Increasing investments in vaccine development by government and private organizations to support market growth	183
11.4.7	REST OF EUROPE	186
11.5	LATIN AMERICA	188
11.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	188
11.5.2	BRAZIL	191
11.5.2.1	Proactive healthcare policies to support market growth	191
11.5.3	MEXICO	194
11.5.3.1	Government commitment to immunization programs to fuel growth	194
11.5.4	REST OF LATIN AMERICA	196
11.6	MIDDLE EAST	198
11.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST	198
11.6.2	GCC COUNTRIES	202
11.6.3	REST OF MIDDLE EAST	204
11.7	AFRICA	206
11.7.1	INCREASING INVESTMENTS IN CANCER VACCINE IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH	206
11.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	207
	?	
12	COMPETITIVE LANDSCAPE	210
12.1	OVERVIEW	210
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023	210
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER VACCINES MARKET	210
12.3	REVENUE ANALYSIS, 2019-2023	212
12.4	MARKET RANKING, 2023 AND 2032	212
12.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	214
12.5.1	STARS	214
12.5.2	EMERGING LEADERS	214
12.5.3	PERVASIVE PLAYERS	215
12.5.4	PARTICIPANTS	215
12.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	216
12.5.5.1	Company footprint	216

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.5.5.2 Region footprint 216
- 12.5.5.3 Type footprint 217
- 12.5.5.4 Technology footprint 217
- 12.5.5.5 Route of administration footprint 218
- 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 218
 - 12.6.1 PROGRESSIVE COMPANIES 218
 - 12.6.2 RESPONSIVE COMPANIES 218
 - 12.6.3 DYNAMIC COMPANIES 218
 - 12.6.4 STARTING BLOCKS 219
 - 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 220
- 12.7 COMPANY VALUATION & FINANCIAL METRICS 221
 - 12.7.1 FINANCIAL METRICS 221
 - 12.7.2 COMPANY VALUATION 221
- 12.8 BRAND/PRODUCT COMPARISON 222
- 12.9 COMPETITIVE SCENARIO 222
 - 12.9.1 PRODUCT LAUNCHES & APPROVALS 222
 - 12.9.2 DEALS 223
 - 12.9.3 EXPANSIONS 224
- 13 COMPANY PROFILES 225
 - 13.1 KEY PLAYERS 225
 - 13.1.1 MERCK & CO., INC. 225
 - 13.1.1.1 Business overview 225
 - 13.1.1.2 Products offered 226
 - 13.1.1.3 Recent developments 227
 - 13.1.1.3.1 Deals 227
 - 13.1.1.3.2 Expansions 227
 - 13.1.1.4 MnM view 228
 - 13.1.1.4.1 Key strengths 228
 - 13.1.1.4.2 Strategic choices 228
 - 13.1.1.4.3 Weaknesses & competitive threats 228
 - 13.1.2 GSK PLC. 229
 - 13.1.2.1 Business overview 229
 - 13.1.2.2 Products offered 230
 - 13.1.2.3 Recent developments 231
 - 13.1.2.3.1 Product approvals 231
 - 13.1.2.4 MnM view 231
 - 13.1.2.4.1 Key strengths 231
 - 13.1.2.4.2 Strategic choices 231
 - 13.1.2.4.3 Weaknesses & competitive threats 231
 - 13.1.3 DENDREON PHARMACEUTICALS LLC. (SANPOWER GROUP) 232
 - 13.1.3.1 Business overview 232
 - 13.1.3.2 Products offered 232
 - 13.1.3.3 MnM view 233
 - 13.1.3.3.1 Key strengths 233
 - 13.1.3.3.2 Strategic choices 233
 - 13.1.3.3.3 Weaknesses & competitive threats 233

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1.4 JW CREAGENE (JW SHINYAK) 234
- 13.1.4.1 Business overview 234
- 13.1.4.2 Products offered 234
- 13.1.5 SERUM INSTITUTE OF INDIA PVT. LTD. 235
- 13.1.5.1 Business overview 235
- 13.1.5.2 Products offered 235
- 13.1.5.3 Recent developments 236
- 13.1.5.3.1 Product launches 236
- 13.1.5.3.2 Deals 236
- 13.1.6 VERITY PHARMACEUTICALS, INC. 237
- 13.1.6.1 Business overview 237
- 13.1.6.2 Products offered 237
- 13.1.6.3 Recent developments 238
- 13.1.6.3.1 Product approvals 238
- 13.1.7 WANTAI BIOPHARM 239
- 13.1.7.1 Business overview 239
- 13.1.7.2 Products offered 239
- 13.1.8 SHANGHAI ZERUN BIOTECH CO., LTD. (WALVAX BIOTECHNOLOGY CO., LTD.) 240
- 13.1.8.1 Business overview 240
- 13.1.8.2 Products offered 240
- 13.1.8.3 Recent developments 241
- 13.1.8.3.1 Product approvals 241
- 13.1.9 VACCINOGEN 242
- 13.1.9.1 Business overview 242
- 13.1.9.2 Products offered 242
- 13.2 OTHER PLAYERS (COMPANIES WITH PRODUCTS UNDER CLINICAL STUDIES) 243
- 13.2.1 BIONTECH 243
- 13.2.1.1 BioNTech: Products under clinical studies 243
- 13.2.2 GRITSTONE BIO 244
- 13.2.2.1 Gritstone Bio: Products under clinical studies 244
- 13.2.3 OSE-IMMUNO 245
- 13.2.3.1 OSE-Immuno: Products under clinical studies 245
- 13.2.4 OBI PHARMA 246
- 13.2.4.1 OBI Pharma: Products under clinical studies 246
- 13.2.5 SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD. 247
- 13.2.5.1 Shanghai Bovax Biotechnology: Products under clinical studies 247
- 13.2.6 MODERNA INC. 248
- 13.2.6.1 Moderna: Products under clinical studies 248
- 13.2.7 BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD. 249
- 13.2.7.1 Beijing Sinocell Biotechnology Group: Products under clinical studies 249
- 13.2.8 GREENWICH LIFESCIENCES, INC. 250
- 13.2.8.1 Greenwich LifeSciences: Products under clinical studies 250
- 13.2.9 ASTON SCI. INC. 251
- 13.2.9.1 Aston Sci.: Products under clinical studies 251
- 13.2.10 TRANSGENE 252
- 13.2.10.1 Transgene: Products under clinical studies 252
- 13.2.11 SELLAS LIFE SCIENCES GROUP INC. 253

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.2.11.1	Sellas Life Sciences Group: Products under clinical studies	253
14	APPENDIX	254
14.1	DISCUSSION GUIDE	254
14.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	259
14.3	CUSTOMIZATION OPTIONS	261
14.4	RELATED REPORTS	261
14.5	AUTHOR DETAILS	262

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032

Market Report | 2024-12-19 | 263 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-10

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com